Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
18 Biggest Mid-Day Gainers For Tuesday
16 Stocks Moving In Tuesday's Pre-Market Session
Related BMY
Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
These Were The Most And Least Popular Stocks In September
Biotech Forum Daily Digest: Election Worries Overblown? Spotlight On Akorn (Seeking Alpha)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

View Comments and Join the Discussion!